PRESS RELEASE published on 06/24/2026 at 17:38, 4 months 10 days ago Form 8.3 - Advanced Medical Sol Group PLC Chelverton Asset Management discloses a 1.29% interest in Advanced Medical Sol Group PLC. Public disclosure according to Rule 8.3 of the Takeover Code Rule 8.3 Takeover Code Chelverton Asset Management Advanced Medical Sol Group PLC 1.29%
BRIEF published on 06/18/2026 at 12:17, 4 months 16 days ago Form 8.3 Filing by Chelverton Asset Management for Advanced Medical Solutions Group Securities Asset Management Disclosure Shareholding Advanced Medical Solutions
BRIEF published on 06/18/2026 at 12:17, 4 months 16 days ago Formulaire 8.3 déposé par Chelverton Asset Management pour Advanced Medical Solutions Group Actionnariat Titres Gestion D'actifs Divulgation Solutions Médicales Avancées
PRESS RELEASE published on 06/18/2026 at 12:12, 4 months 16 days ago Form 8.3 - Advanced Medical Solutions Group Plc Chelverton Asset Management discloses a 1.33% stake in Advanced Medical Solutions Group Plc in a Form 8.3 filing on 17 June 2026 Form 8.3 Financial Filing Stake Disclosure Chelverton Asset Management Advanced Medical Solutions Group Plc
BRIEF published on 06/16/2026 at 15:36, 4 months 18 days ago Apex Fundrock Limited annonce une prise de participation dans Reabold Resources PLC Code De Prise De Contrôle Information Sur Les Valeurs Mobilières Apex Fundrock Poste À Pourvoir Ressources Reabold
BRIEF published on 06/16/2026 at 15:36, 4 months 18 days ago Apex Fundrock Limited Discloses Opening Position in Reabold Resources PLC Takeover Code Securities Disclosure Apex Fundrock Opening Position Reabold Resources
PRESS RELEASE published on 06/16/2026 at 15:31, 4 months 18 days ago Form 8.3 - REABOLD RESOURCES PLC : Opening Position Disclosure Chelverton Asset Management discloses opening position of 3.18% in Reabold Resources PLC in accordance with Rule 8.3 of the Takeover Code Opening Position Disclosure Rule 8.3 Takeover Code Chelverton Asset Management Reabold Resources PLC
BRIEF published on 06/11/2026 at 14:12, 4 months 23 days ago Disclosure of Interests in Advanced Medical Solutions Group PLC Takeover Code Financial Disclosure Chelverton Asset Management Advanced Medical Solutions Investment Positions
BRIEF published on 06/11/2026 at 14:12, 4 months 23 days ago Déclaration des intérêts dans Advanced Medical Solutions Group PLC Code De Prise De Contrôle Déclaration Financière Positions D'investissement Solutions Médicales Avancées Gestion D'actifs De Chelsea
PRESS RELEASE published on 06/11/2026 at 14:07, 4 months 23 days ago Form 8.3 - ADVANCED MEDICAL SOLUTIONS GROUP PLC Chelverton Asset Management discloses a 1.34% ownership in ADVANCED MEDICAL SOL GROUP PLC through Apex Fundrock Limited. Dealing took place on 10 June 2026 Dealing Disclosure Apex Fundrock Limited Ownership Disclosure Chelverton Asset Management Advanced Medical Sol Group PLC
Published on 11/04/2026 at 23:10, 4 hours 54 minutes ago Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 5 hours 4 minutes ago Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 5 hours 49 minutes ago Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 5 hours 59 minutes ago Stabilis Solutions Announces Third Quarter 2026 Results
Published on 11/05/2026 at 03:55, 9 minutes ago AlphaESS Named a BloombergNEF Tier 1 Energy Storage Manufacturer for the Fifth Consecutive Quarter in Q4 2026
Published on 11/05/2026 at 03:10, 54 minutes ago SensAI Veritas Launches SensAI Gateway™ and SensAI Helm™: Bringing Risk Intelligence to the Moment of Trust
Published on 11/05/2026 at 00:02, 4 hours 1 minute ago EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Published on 11/04/2026 at 19:41, 8 hours 23 minutes ago EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 8 hours 39 minutes ago Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:00, 10 hours 4 minutes ago The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 10 hours 4 minutes ago L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:44, 10 hours 20 minutes ago Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026
